TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive In Brief: NCI awards center Grant to Cancer Institute of New Jersey; Researcher Win Honors April 4, 1997